Larimar Therapeutics (LRMR) Capital Expenditures Growth (3y) (2016 - 2025)
Larimar Therapeutics (LRMR) Capital Expenditures Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -56.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -56.05% |
| Sep 30, 2025 | 1.07% |
| Jun 30, 2025 | -6.71% |
| Mar 31, 2025 | -141.01% |
| Dec 31, 2024 | -17.95% |
| Sep 30, 2024 | 51.41% |
| Jun 30, 2024 | 18.64% |
| Mar 31, 2024 | -61.42% |
| Dec 31, 2023 | -12.99% |
| Sep 30, 2023 | -58.74% |
| Jun 30, 2023 | -40.51% |
| Mar 31, 2023 | -100.00% |
| Dec 31, 2022 | -31.29% |
| Sep 30, 2022 | -56.41% |
| Jun 30, 2022 | 154.21% |
| Mar 31, 2022 | -35.72% |
| Dec 31, 2021 | 46.05% |
| Sep 30, 2021 | -123.01% |
| Jun 30, 2021 | -72.35% |
| Mar 31, 2021 | 591.74% |